Erschienen in:
01.06.2007 | Lab Investigation
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
verfasst von:
Emmanuelle Crinière, Gentian Kaloshi, Florence Laigle-Donadey, Julie Lejeune, Nathalie Auger, Alexandra Benouaich-Amiel, Sibille Everhard, Karima Mokhtari, Marc Polivka, Jean-Yves Delattre, Khê Hoang-Xuan, Joëlle Thillet, Marc Sanson
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 2/2007
Einloggen, um Zugang zu erhalten
Abstract
MGMT promoter methylation, which has been correlated with the response to alkylating agents, was investigated in a retrospective series of 219 glioblastomas (GBMs) treated with various modalities. MGMT methylation had no impact on survival for the whole group, but showed a significant advantage (17.1 months vs. 13.1) for patients treated with RT+ adjuvant chemotherapy (relative risk of death (RR) = 0.53; P = 0.041), particularly when patients received CT during the course of RT (MS = 19.9 months vs. 12.5 months; RR = 0.227, P = 0.001). This suggests that the prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules. MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression.